Sept. 17, 2013 — Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan IM, Adequan IA and Adequan Canine, provided the following supply update:

We are pleased to announce a shipment of Adequan (polysulfated glycosaminoglycan) IM was released to the market last week and was received by veterinarians beginning Friday, Sept. 13. Adequan product supply remains limited and the initial shipments will not fully satisfy market demand. Luitpold made significant investments in upgrading its manufacturing facilities earlier this year. The time spent making these upgrades impacted our ability to keep up with demand. We are working diligently to release additional product to the market and will provide updates as they become available. Quality and integrity remain our highest priorities.

We encourage Adequan users to continue to work with their veterinarians to obtain the drug and discuss the most appropriate treatment regimen for your animals.

Luitpold has established a dedicated webpage on www.adequan.com where concerned parties can register to receive future communications and updates on this matter. You may also contact our Customer Service Department at 1-800-458-0163.

Adequan IM and IA are the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses.

Adequan Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

There are no known contraindications to the use of intramuscular Adequan IM brand polysulfated glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Each 5 mL contains 500 mg polysulfated glycosaminoglycan. Brief Summary Indications: For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

Inflammatory joint reactions and septic arthritis have been reported following administration of Adequan IA. Joint sepsis, a rare but potentially life-threatening complication, can occur after intra-articular injection. Use only in the carpal joint of horses. Do not use in horses intended for human consumption.

Adequan Canine (polysulfated glycosaminoglycan or PSGAG) should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment.